With Roche Deal Signed, Tekmira Says It Has Funds to Last Until Mid-2011
May 14, 2009
With Roche Deal Signed, Tekmira Says It Has Funds to Last Until Mid-2011
Tekmira made the disclosure as part of its first-quarter earnings release, which showed a 425 percent rise in net loss as operations swelled after its merger with Protiva Biotherapeutics last year.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UniQure, Collaborators Secure $3.2M Eurostar Grant for Huntington’s Disease Effort
May 23, 2013 / Gene Silencing News - NIH Awards $400K to Fund Three microRNA Research Grants in May
May 23, 2013 / Gene Silencing News - Alnylam Releases Proof-of-concept Data on Preclinical Porphyria Drug
May 23, 2013 / Gene Silencing News - MiRagen Hits First Milestone in Servier microRNA Drug Partnership
May 23, 2013 / Gene Silencing News - Cenix to Provide Research Services to Debiopharm
May 23, 2013 / Gene Silencing News